Asker Healthcare (ASKER) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Asker Healthcare stock SEK 28.26, price SEK 76.10, that is 62.9% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
19‑month range kr 56.65 – kr 130.59 · fair‑value band kr 20.72 – kr 35.32 · the kr 76.10 price screens above the kr 28.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Asker Healthcare in your weekly email
Every Wednesday you see whether Asker Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care.
Show moreShow less
The company supplies and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products.
In addition, it develops and sells disposable medical supplies under the Evercare, Selefa, and Embra brands; distributes eye surgery products; and develops and sells products for time-management, communication, and cognition for schools, assistive technology centres, and other public services.
Further, the company provides support and assistance to people needing wound, diabetes, and urological care; ostomy, urology, and rehab services; ambulance services; and products for physiotherapy practices, as well as supplies exercise and treatment equipment and measurement.
Additionally, it sells and rents out various mobility aids and rehab products, such as pressure-relieving mattresses and cushions, as well as manufactures and distributes pressure care products.
The company operates in Sweden, Norway, Finland, Estonia, Latvia, Lithuania, Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, France, Slovakia, Czech Republic, and Poland.
Asker Healthcare Group AB (publ) was founded in 2006 and is headquartered in Danderyd, Sweden.
Stock analysis
Asker Healthcare (ASKER) currently trades at kr 76.10, while our model-based Fair Value estimate is kr 28.26, 63% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 53.73 per share, and 0 of the 22 models we run sit above the kr 76.10 price.
Bear case: the Economic Profit group reads lowest at kr 14.77, and 22 of the 22 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 20.72 (bear) to kr 35.32 (bull), the price of kr 76.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Asker Healthcare reported revenue of 16.8B SEK in FY2025 versus 9.4B SEK in FY2021, a compound +15.7%/yr. Reported net income was 492M SEK in FY2025, compounding +1.3%/yr from FY2021.
Key figures
Market cap 29.1B SEK (≈ $2.9B) Mid · P/E ratio 38.8 · P/S ratio 1.56 · EPS (TTM) kr 1.96 · Dividend yield 0.5% · Net margin 4.1% · Return on equity 11.2% · Return on assets (EBIT) 6.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 34% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −63%, ASKER screens richer than that median.
Fair Value models
Bearkr 20.72Fair Value kr 28.26Bullkr 35.32
Price kr 76.10 · Downside -62.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 1.34 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+2.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.8%
Dividend (yield on the price)0.5%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 6%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +21.7% a year for the price and +6.8% for the forecasts.
AI conclusion: Targeted acquisitions build scale in a fragmented medical distribution sector while a new warehouse supports future cost savings, yet limited public data and moderate returns leave business quality hard to confirm.
Main risk: Reimbursement shifts and thin margins typical in pharmaceutical distribution could pressure volumes and overall profitability across the medical products business.
Asker expands through targeted acquisitions in medical distribution while a new Gothenburg warehouse is set to deliver annual savings starting in the second half of 2027. These moves target better scale and margins in a fragmented sector, yet our models view the stock as overvalued. Will the platform growth and cost efficiencies outweigh the valuation concerns or leave the shares exposed?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−62.9% · Bottom 25%
Profitability
Return on equity (12 months)11.2% · Top 25%
Return on assets2.9% · Above median
Net margin (12 months)4.1% · Above median
Operating margin (12 months)6.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)15.2% · Top 25%
Dividend yield (12 months)0.5% · Bottom 25%
Balance sheet
Debt / equity0.64× · Highest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (12 months)38.8× · Priciest 25%
P/B4.45× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Asker Healthcare Fair Value". https://www.fairvalue-calculator.com/stock/ASKER
Frequently asked questions
Is Asker Healthcare (ASKER) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of kr 28.26 versus a price of kr 76.10, about 63% lower (overvalued).
What is the fair value of ASKER?
Our model-based fair value for Asker Healthcare is kr 28.26 (as of Nov 7, 2026), built from audited fundamentals. The current price: kr 76.10.
What is the quality score of ASKER?
Asker Healthcare has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Asker Healthcare (ASKER)?
Our model-based price target is the fair value of kr 28.26 (as of Nov 7, 2026) from 22 valuation models. Cautious scenario kr 20.72, optimistic scenario kr 35.32. It is a calculation from audited fundamentals, not an analyst target.
What is the Asker Healthcare stock forecast for 2026?
Our models put fair value at kr 28.26, about 63% lower versus a price of kr 76.10 (overvalued). Cautious scenario kr 20.72, optimistic scenario kr 35.32. The calculation is refreshed regularly with new filings.
What is the revenue of Asker Healthcare (ASKER)?
Asker Healthcare reported trailing-twelve-month revenue of about 18.6B SEK (latest available figure, as of Nov 7, 2026).
Does Asker Healthcare pay a dividend?
Asker Healthcare currently shows a dividend yield of 0.51% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Asker Healthcare (ASKER) and when is the ex-dividend date?
Asker Healthcare pays a dividend of kr 0.39 per share a year, a dividend yield of 0.5%. The last ex-dividend date was May 8, 2026. The payout ratio is 14.5% of earnings (on adjusted earnings, reported 19.9%). Free cash flow covers the dividend 4.94 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Asker Healthcare (ASKER)?
For today's price to be fair in a discounted-cash-flow model, Asker Healthcare would have to grow free cash flow by +24.2 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +15.7 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of ASKER use?
Our models discount Asker Healthcare at 9.5 %: a base by market capitalisation (mid), country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Asker Healthcare that is +24.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Asker Healthcare (ASKER) delivered so far?
Over the past 4 years revenue at Asker Healthcare grew +15.7 % a year. The price currently implies free-cash-flow growth of +24.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Asker Healthcare (ASKER) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Asker Healthcare (+24.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Asker Healthcare (ASKER)?
The free-cash-flow yield on the price is 2.53 %: that much free cash flow Asker Healthcare produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Asker Healthcare (ASKER)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Asker Healthcare it is kr 28.26 per share (as of Nov 7, 2026), against a price of kr 76.10. It is the blended result of 22 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Asker Healthcare stock overvalued or undervalued in 2026?
As of Nov 7, 2026, ASKER trades above its calculated fair value: price kr 76.10, fair value kr 28.26, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASKER?
No. The price is what the market pays today (kr 76.10); the fair value is what the company's own numbers justify (kr 28.26). For Asker Healthcare the two are kr 47.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Asker Healthcare worth?
The market values Asker Healthcare at about 29.1B SEK (market capitalisation, as of Nov 7, 2026). Per share that is kr 76.10; our models calculate a fair value of kr 28.26 per share.
What do the bullish and bearish scenarios say about ASKER?
Our models span a range for Asker Healthcare: cautious scenario kr 20.72, base kr 28.26, optimistic kr 35.32 per share (as of Nov 7, 2026, price kr 76.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ASKER?
Asker Healthcare trades at a price-to-earnings ratio of 38.8 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 28.26 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 43.1 (reported for FY2025: 59.2). Other multiples: P/B 4.5, P/S 1.6, EV/EBITDA 17.0.
How solid is the balance sheet of Asker Healthcare (ASKER)?
Balance-sheet figures for Asker Healthcare (as of Nov 7, 2026): return on equity 11.2%, debt of 0.64 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is ASKER from its 52-week high?
Asker Healthcare trades at kr 76.10, about 19% below its 52-week high of kr 93.95 and 34% above the low of kr 56.65 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 28.26 is for.
Which stocks are comparable to Asker Healthcare?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Asker Healthcare stock attractive at the current price?
The data as of Nov 7, 2026: price kr 76.10, calculated fair value kr 28.26 (−63%), Quality Score 47/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ASKER calculated?
We run Asker Healthcare through 22 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 28.26 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Asker Healthcare itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Asker Healthcare (ASKER)?
The closing price on Nov 6, 2026 was kr 76.10. Our model-based fair value is kr 28.26, about 63% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Asker Healthcare right now?
The price sits above even our optimistic bull case (kr 35.32). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Asker Healthcare
How large is the market capitalisation of Asker Healthcare (ASKER)?
The market capitalisation of Asker Healthcare is 29.1B SEK (≈ $2.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Asker Healthcare (ASKER)?
The price-to-sales ratio of Asker Healthcare is 1.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Asker Healthcare (ASKER)?
Earnings per share at Asker Healthcare are kr 1.96 (price ÷ EPS = P/E 38.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Asker Healthcare (ASKER)?
The dividend yield of Asker Healthcare is 0.5% (payout 14.5%, on adjusted earnings, reported 19.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Asker Healthcare (ASKER)?
The net margin of Asker Healthcare is 4.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Asker Healthcare (ASKER)?
The return on equity (ROE) of Asker Healthcare is 11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Asker Healthcare (ASKER)?
On an EBIT basis the return on assets of Asker Healthcare is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Asker Healthcare (ASKER)?
The operating margin of Asker Healthcare is 6.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Asker Healthcare (ASKER)?
Revenue at Asker Healthcare is growing +15.2% versus a year earlier (3y avg +12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Asker Healthcare (ASKER)?
Earnings per share at Asker Healthcare are growing +50.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Asker Healthcare (ASKER) carry?
The net debt of Asker Healthcare is 4.9B SEK (fiscal year 2025, ≈ 6.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Asker Healthcare in the live analysis
One click puts Asker Healthcare on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026